Viatris Inc.

Report azionario NasdaqGS:VTRS

Capitalizzazione di mercato: US$19.0b

Viatris Crescita futura

Criteri Future verificati 4/6

Viatris prevede che gli utili e i ricavi cresceranno rispettivamente di 50.6% e 1.9% all'anno. Si prevede che l'EPS crescerà di 41.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 21.9% in 3 anni.

Informazioni chiave

50.6%

Tasso di crescita degli utili

41.88%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili14.9%
Tasso di crescita dei ricavi1.9%
Rendimento futuro del capitale proprio21.87%
Copertura analitica

Good

Ultimo aggiornamento12 Jun 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Jun 23

Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)

Summary Viatris Inc. ends the first half of 2026 on a high note. On May 8, its stock reached a 52-week high of $17.53. One of the key drivers behind Viatris' recent rally is its pipeline, which includes more than 10 late-stage product candidates. However, after peaking in mid-May, VTRS shares entered a correction phase, which I believe was partly caused by a 9% QoQ decline in Effexor sales to $62 million in Q1. In this article, you'll learn why I believe VTRS stock's risk/reward has become balanced. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Jun 16

VTRS: Pipeline Execution And Euro Debt Raise Will Pressure Elevated Expectations

Analysts have raised the Viatris price target by $5 to $22, citing stronger modeled revenue growth, a slightly adjusted profit margin profile, and expectations that ongoing product approvals could support a somewhat higher future P/E multiple. Analyst Commentary Recent Street research around Viatris centers on how the stock lines up on valuation against peers, how reliable the current execution looks, and what the growth path might be over the next few years.
Aggiornamento della narrazione • Jun 01

VTRS: Product Approval Execution Will Test Elevated Future Earnings Expectations

Analysts have raised their Viatris price target by $5 to $22, citing strong Q1 results and expectations that upcoming product approvals and a narrowing revenue growth gap to peers could support a higher valuation multiple over time. Analyst Commentary Street research on Viatris has recently tilted more constructive around the Q1 print, but even the more optimistic voices are still flagging execution and durability risks around the story.
Aggiornamento della narrazione • May 18

VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential

Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.
Aggiornamento della narrazione • May 03

VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential

Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.
Aggiornamento della narrazione • Apr 19

VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential

Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.
Aggiornamento della narrazione • Apr 04

VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential

Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
Aggiornamento della narrazione • Mar 21

VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential

Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
Aggiornamento della narrazione • Mar 07

VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations

Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.
Aggiornamento della narrazione • Feb 20

VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk

Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.
Aggiornamento della narrazione • Feb 06

VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential

Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.
Aggiornamento della narrazione • Jan 23

VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential

Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.
Aggiornamento della narrazione • Jan 09

VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns

Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.
Aggiornamento della narrazione • Dec 25

VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance

Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.
Aggiornamento della narrazione • Dec 11

VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance

Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.
Aggiornamento della narrazione • Nov 27

VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead

Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.
Aggiornamento della narrazione • Nov 13

VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead

The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.
Aggiornamento della narrazione • Oct 30

VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth

Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.
Aggiornamento della narrazione • Oct 15

Aging Populations And Asia Markets Will Unlock Future Value

Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.
Aggiornamento della narrazione • Aug 27

Aging Populations And Asia Markets Will Unlock Future Value

The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
User avatar
Nuova narrazione • Apr 22

New Product Launches And Expense Savings Will Strengthen Future Operations

New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.
Seeking Alpha • Feb 27

Viatris: One Swallow Doesn't Make A Summer

Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out

Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes

Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:VTRS - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202815,3379771,7472,8705
12/31/202715,0384981,4912,9077
12/31/202614,774131,3372,2477
3/31/202614,563-2961,6562,169N/A
12/31/202514,300-3,5151,8512,316N/A
9/30/202514,124-3,6911,5991,983N/A
6/30/202514,116-3,4681,6952,064N/A
3/31/202514,330-3,7901,8392,224N/A
12/31/202414,739-6341,9442,303N/A
9/30/202415,049-8831,8932,389N/A
6/30/202415,239-6461,8842,397N/A
3/31/202415,361-562,0002,543N/A
12/31/202315,427552,3252,900N/A
9/30/202315,4661,8322,0232,474N/A
6/30/202315,6021,8542,0452,508N/A
3/31/202315,8001,9042,3322,785N/A
12/31/202216,2632,0792,5102,999N/A
9/30/202216,7288042,8353,333N/A
6/30/202217,1877613,0353,550N/A
3/31/202217,6481682,7793,307N/A
12/31/202117,886-1,2692,5083,017N/A
9/30/202117,168-1,9211,7842,530N/A
6/30/202115,604-2,0471,2961,969N/A
3/31/202113,757-1,7281,1661,790N/A
12/31/202011,946-6705511,232N/A
9/30/202011,5142661,5391,882N/A
6/30/202011,5042711,5021,845N/A
3/31/202011,624631,6872,135N/A
12/31/201911,50117N/A1,804N/A
9/30/201911,38748N/A1,753N/A
6/30/201911,28834N/A1,919N/A
3/31/201911,245240N/A1,680N/A
12/31/201811,434353N/A2,342N/A
9/30/201811,594546N/A2,201N/A
6/30/201811,719457N/A2,096N/A
3/31/201811,873717N/A2,234N/A
12/31/201711,908696N/A2,065N/A
9/30/201711,937869N/A1,919N/A
6/30/201712,007661N/A2,571N/A
3/31/201711,605533N/A2,420N/A
12/31/201611,077480N/A2,047N/A
9/30/201610,300257N/A2,350N/A
6/30/20169,938806N/A2,124N/A
3/31/20169,749805N/A1,822N/A
12/31/20159,429848N/A2,009N/A
9/30/20159,021842N/A1,483N/A
6/30/20158,410913N/A949N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che VTRS diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che VTRS diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede VTRS diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di VTRS ( 1.9% all'anno) crescerà più lentamente rispetto al mercato US ( 12.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di VTRS ( 1.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di VTRS sarà elevato tra 3 anni ( 21.9 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/29 07:13
Prezzo dell'azione a fine giornata2026/06/29 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Viatris Inc. è coperta da 31 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jasper HellwegArgus Research Company
Glen SantangeloBarclays
Aaron GalBernstein